{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:06:32Z","timestamp":1789059992303,"version":"build-2803163510"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013142","name":"Key Research and Development Project of Hainan Province","doi-asserted-by":"publisher","award":["231111313300"],"award-info":[{"award-number":["231111313300"]}],"id":[{"id":"10.13039\/501100013142","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejca.2026.116986","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T22:23:38Z","timestamp":1786227818000},"page":"116986","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["High-dose furmonertinib plus bevacizumab and intrathecal pemetrexed for EGFR-RAD51 fusion-positive lung adenocarcinoma with leptomeningeal metastasis: Insights from serial CSF ctDNA monitoring"],"prefix":"10.1016","volume":"246","author":[{"given":"Cuicui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuzhou","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3217-1077","authenticated-orcid":false,"given":"Qiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2026.116986_bib1","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.pccm.2025.04.001","article-title":"Temporal trends in the burden of tracheal, bronchial, and lung cancer in China and globally: a comprehensive analysis from 1990 to 2021","volume":"3","author":"Fan","year":"2025","journal-title":"Chin Med J Pulm Crit Care Med"},{"issue":"8","key":"10.1016\/j.ejca.2026.116986_bib2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2213-2600(20)30455-0","article-title":"Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study","volume":"9","author":"Shi","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"11","key":"10.1016\/j.ejca.2026.116986_bib3","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","article-title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.ejca.2026.116986_bib4","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1158\/2159-8290.CD-16-0075","article-title":"EGFR fusions as novel therapeutic targets in lung cancer","volume":"6","author":"Konduri","year":"2016","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.ejca.2026.116986_bib5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jtho.2024.09.1385","article-title":"High-dose furmonertinib in patients with EGFR-mutated NSCLC and leptomeningeal metastases: a prospective real-world study","volume":"20","author":"Chen","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116986_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.107743","article-title":"Furmonertinib-based triplet therapy improves survival in EGFR-mutant NSCLC with leptomeningeal metastases: a large-scale multicenter retrospective study (FURMO-LM)","volume":"11","author":"Chen","year":"2026","journal-title":"ESMO Open"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:09:05Z","timestamp":1789056545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926007677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":6,"alternative-id":["S0959804926007677"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116986","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-dose furmonertinib plus bevacizumab and intrathecal pemetrexed for EGFR-RAD51 fusion-positive lung adenocarcinoma with leptomeningeal metastasis: Insights from serial CSF ctDNA monitoring","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116986","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116986"}}